Alexion Pharmaceuticals, Inc., a biotechnology company, develops and delivers life-changing drug therapies for patients with serious and life-threatening medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. The company markets Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder in the United States and Europe. It also is evaluating other potential indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, it is developing antibody product candidates targeting the treatment of patients with severe unmet medical needs. The company's drug programs comprise DC-SIGN Mab, a cancer Vaccine; Eculizumab (intravitreal) for age-related macular degeneration; and Eculizumab (intravenous) for myasthenia gravis and multifocal motor neuropathy, which are under preclinical development stage; CD200 Mab for the treatment of chronic lymphocytic leukemia and multiple myeloma under Phase I clinical trial; and Eculizumab (intravenous) under Phase I/II clinical trial for the treatment of asthma. . Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut.
Headquartered in Cheshire, Connecticut, Alexion employs more than 700 people around the world. In addition to our corporate headquarters, Alexion’s facilities include a manufacturing plant in Smithfield, Rhode Island, EMEA (Europe, Middle East & Africa) regional headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Tokyo, Japan, Sydney, Australia, São Paulo, Brazil, Ontario, Canada and other countries. The company is also expanding its reach in Latin America, the Middle East and Africa.
Alexion’s global presence reflects the approval of Soliris for the treatment of patients with PNH in the United States, 29 European countries, Australia, Canada and other countries. The company is working toward seeking regulatory approval in other countries of Asia and South America.